

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

25 Jun 2026

### The efficacy of complementary use of memantine in treatment of schizophrenia with chronic course

#### Protocol summary

##### Summary

Objectives: This study aimed at evaluating the efficacy of complementary use of memantine in treatment of schizophrenia with chronic course Design: Clinical trial study Setting and conduct: Clinical trial study in educational center Participants including major eligibility criteria: Sixty patients with chronic schizophrenic will be evaluated. Schizophrenic patients are randomly divided into two groups. Intervention: The first group will be treated with oral Risperidone 6 mg per day and 5-20 mg Memantine (n=30) and the other group will be received Risperidone 6 mg per day and placebo (n = 30). Main outcome: Change drastically from week zero to week 8 based on the Positive and Negative Scale will be measured. Patients will be evaluated in regard of extrapyramidal side effects and complications.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201306015605N1**  
Registration date: **2013-10-19, 1392/07/27**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2013-10-19, 1392/07/27

##### Registrant information

###### Name

MOHAMAD GOLDUST

###### Name of organization / entity

Tabriz University of medical sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 41133614711

###### Email address

medres@tbzmed.ac.ir

###### Recruitment status

**Recruitment complete**

###### Funding source

Clinical psychiatry research center, Tabriz university of medical sciences

###### Expected recruitment start date

2012-11-20, 1391/08/30

###### Expected recruitment end date

2013-11-20, 1392/08/29

###### Actual recruitment start date

empty

###### Actual recruitment end date

empty

###### Trial completion date

empty

###### Scientific title

The efficacy of complementary use of memantine in treatment of schizophrenia with chronic course

###### Public title

The efficacy of complementary use of memantine in treatment of schizophrenia with chronic course

###### Purpose

Treatment

###### Inclusion/Exclusion criteria

Exclusion criteria: Substance abuse; IQ of less than 70; Medical history of other mental disorder; Other clinical and neurological disorders; Taking antipsychotic medications during last week or long acting antipsychotic medications during past month; Receiving ECT in the past two weeks; Sensitivity to Memantine

###### Age

No age limit

###### Gender

Both

## Phase

2

### Groups that have been masked

No information

### Sample size

Target sample size: 60

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Not blinded

### Blinding description

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethic committee of Tabriz university of medical sciences

##### Street address

5166614711, University street, Tabriz, Iran

##### City

Tabriz

##### Postal code

#### Approval date

2011-06-12, 1390/03/22

#### Ethics committee reference number

91147

## Health conditions studied

### 1

#### Description of health condition studied

Schizophrenia

#### ICD-10 code

F20

#### ICD-10 code description

Schizophrenia

## Primary outcomes

### 1

#### Description

Schizophrenia severity

#### Timepoint

6 months

#### Method of measurement

Clinical assesment

## Secondary outcomes

### 1

#### Description

Side effects

#### Timepoint

Two month after begining of the study

#### Method of measurement

Clinical assessment

## Intervention groups

### 1

#### Description

The control group will be received Risperidone 6 mg per day and placebo (n = 30).

#### Category

Treatment - Drugs

### 2

#### Description

The case group will be treated with oral Risperidone 6 mg per day and 5-20 mg Memantine (n=30)

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Department of psychiatrics, Razi hospital

##### Full name of responsible person

Dr Ali Fakhari

##### Street address

5166614711, El goli street, Tabriz, Iran

##### City

Tabriz

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Clinical psychiatry research center, Tabriz university of medical sciences

##### Full name of responsible person

Ali Fakhari

##### Street address

5166614711, El goli street, Tabriz, Iran

##### City

Tabriz

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

**Title of funding source**

Clinical psychiatry research center, Tabriz university of medical sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Tabriz university of medical sciences

**Full name of responsible person**

Dr Ashkan Yousefi

**Position**

Resident in Psychiatrics

**Other areas of specialty/work**

**Street address**

5166614711, El goli street, Tabriz, Iran

**City**

Tabriz

**Postal code**

**Phone**

+98 41 1545 2206

**Fax**

**Email**

Drmjgoldust@gmail.com

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tabriz university of medical sciences

**Full name of responsible person**

Dr Ali Fakhari

**Position**

Associate professor in psychiatrics

**Other areas of specialty/work**

**Street address**

5166614711, El goli street, Tabriz, Iran

**City**

Tabriz

**Postal code**

**Phone**

+98 41 1545 2206

**Fax**

**Email**

fakharia@tbzmed.ac.ir

**Web page address**

**Person responsible for updating data**

**Contact**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*